| A839 |
Lampalizumab
Featured
|
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. |
|
| A840 |
Novelmed patent anti-Properdin
Featured
|
|
|
| A841 |
Regeneron patent anti-RET
Featured
|
|
|
| A842 |
Oxford Bio patent anti-CRTAM
Featured
|
|
|
| A843 |
Cabiralizumab
Featured
|
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research. |
|
| A844 |
Axatilimab
Featured
|
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases. |
|
| A845 |
Emactuzumab
Featured
|
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) . |
|
| DC67197 |
m7GpppAmpG ammonium
Featured
|
m7GpppAmpG ammonium is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 90%.
|
|
| A846 |
LY3022855
Featured
|
|
|
| A847 |
Lenzilumab
Featured
|
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies. |
|
| A848 |
Gimsilumab
Featured
|
Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA). |
|
| A849 |
Namilumab
Featured
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis. |
|
| A850 |
Plonmarlimab
Featured
|
Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19. |
|
| A851 |
Theraclone patent anti-GM-CSF
Featured
|
|
|
| DC60709 |
BAL-0028
Featured
|
BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC50 value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with KD values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity. |
|
| DC67198 |
Tulathromycin B
Featured
|
Tulathromycin B (CP 547272) is an isomer of Tulathromycin (a macrolide antibiotic). |
|
| DC67199 |
Virginiamycin M1
Featured
|
Virginiamycin M1 (Pristinamycin IIA; Ostreogrycin A), produced by Streptomyces virginiae, is an polyunsaturated macrocyclic lactone antibiotic and acts as a component of Virginiamycin (HY-112665). Virginiamycin M1 alone is against Staphylococcus aureus with a MIC of 0.25 μg/mL. |
|
| DC67200 |
FR179642 hydrate
Featured
|
FR179642 hydrate is the cyclic peptide nucleus of the lipopeptide antifungal FR901379 and an intermediate in the synthesis of the echinocandin antifungal FK463. |
|
| DC67201 |
Pneumocandin C0 (9CI)
Featured
|
Pneumocandin C0 is the isomer of Pneumocandin B0 (HY-17578) with antifungal activity, which is found by carrying out fermentations of Glarea lozoyensis at a high residual fructose concentration. |
|
| DC67202 |
Pneumocandin E0
Featured
|
|
|
| DC67203 |
ZERANOL
Featured
|
|
|
| DC67204 |
Chloroorienticin A
Featured
|
Chloroorienticin A (A82846B) is a glycopeptide antibiotic. Chloroorienticin A exhibits excellent activity against staphylococci and streptococci. |
|
| DC67205 |
Daunorubicin EP Impurity B
Featured
|
|
|
| DC67206 |
Cp2-S04
Featured
|
|
|
| DC67207 |
Flecainide hydrochloride
Featured
|
Flecainide hydrochloride is a potent and orally active antiarrhythmic agent widely used in the treatment of various cardiac arrhythmias. It belongs to the class IC antiarrhythmic drugs, which are known for their strong sodium channel-blocking properties. Flecainide hydrochloride primarily works by inhibiting the cardiac fast inward sodium current (INa) and the rapid component of the delayed rectifier potassium current (IKr), leading to a prolongation of the action potential duration (APD) in both ventricular and atrial muscle fibers. Its unique electrophysiological effects make it particularly effective in managing certain types of arrhythmias, including fetal tachycardias. |
|
| DC67208 |
INF 195
Featured
|
INF 195 is a potent and selective NLRP3 inflammasome inhibitor that has shown significant promise in preclinical studies for its ability to inhibit NLRP3-driven inflammatory responses, including macrophage pyroptosis and IL-1β release. By targeting the NLRP3 inflammasome, INF 195 has demonstrated therapeutic potential in conditions involving excessive inflammation, such as myocardial ischemia/reperfusion injury (IRI). |
|
| DC67209 |
Kif18A-IN-6
Featured
|
KIF18A-IN-6 (Compound 134) is a highly potent and orally active KIF18A inhibitor with significant potential for cancer therapy. Its ability to disrupt mitosis and induce apoptosis in cancer cells makes it a promising candidate for targeting chromosomally unstable tumors and advancing cancer research. |
|
| A852 |
Mavrilimumab
Featured
|
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. |
|
| A853 |
Trabikibart
Featured
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research. |
|
| A854 |
Anumigilimab
Featured
|
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation. |
|
